NCT02503358View on ClinicalTrials.gov

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 21, 2016

Primary Completion Date

July 16, 2020

Study Completion Date

July 16, 2020

Conditions
Stage IIIB Non-Small Cell Lung Cancer AJCC v7Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

OTHER

Pharmacological Study

Correlative studies

DRUG

Selumetinib

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER